In a market that has grown wary of “story stocks,” Eupraxia Pharmaceuticals (NASDAQ: EPRX) just delivered something refreshingly old-fashioned: a fully closed, upsized equity offering that actually funds a clinical plan rather than a marketing slogan. The clinical‑stage biotech, which trades on…